EichorEICHOR
Location: Meriden Synced from ClinicalTrials.gov · August 07, 2026

Clinical studies recruiting near Meriden

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-S
Phase 3 · Midstate Medical Center · National Cancer Institute (NCI) · NCT06498635Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Phase 3 · Midstate Medical Center · ECOG-ACRIN Cancer Research Group · NCT04566328mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg
Phase 3 · Midstate Medical Center · Alliance for Clinical Trials in Oncology · NCT05677490Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Remo
Phase 2/Phase 3 · Midstate Medical Center · National Cancer Institute (NCI) · NCT05987241Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Phase 2/Phase 3 · Midstate Medical Center · SWOG Cancer Research Network · NCT03851445Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Phase 3 · Midstate Medical Center · National Cancer Institute (NCI) · NCT04181060Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After
Phase 3 · Midstate Medical Center · Alliance for Clinical Trials in Oncology · NCT05812807TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumo
Phase 2 · Midstate Medical Center (MSMC) · American Society of Clinical Oncology · NCT02693535Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Phase N/A · Midstate Medical Center · SWOG Cancer Research Network · NCT04871542Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal
Phase 3 · Midstate Medical Center · NRG Oncology · NCT05879926Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Know
Phase 3 · Midstate Medical Center · Alliance for Clinical Trials in Oncology · NCT06661720Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Phase 3 · Midstate Medical Center · SWOG Cancer Research Network · NCT05929768
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.